These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24220697)

  • 21. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term prognosis of childhood hepatoblastoma in relation to ERCC1 C118T single nucleotide polymorphism and VEGF expression.
    Wen Y; Zhang W; Zhang Y; Hu H; Li J; Huang D
    Pol J Pathol; 2019; 70(4):304-310. PubMed ID: 32146800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs.
    Andersson BS; Sadeghi T; Siciliano MJ; Legerski R; Murray D
    Cancer Chemother Pharmacol; 1996; 38(5):406-16. PubMed ID: 8765433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer.
    Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H
    Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
    Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.
    Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
    Oncol Res Treat; 2020; 43(4):160-169. PubMed ID: 31958797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
    Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
    Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological and predictive role of ERCC1 polymorphisms in cancer.
    Formica V; Doldo E; Antonetti FR; Nardecchia A; Ferroni P; Riondino S; Morelli C; Arkenau HT; Guadagni F; Orlandi A; Roselli M
    Crit Rev Oncol Hematol; 2017 Mar; 111():133-143. PubMed ID: 28259288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients.
    Avinash Tejasvi ML; Maragathavalli G; Putcha UK; Ramakrishna M; Vijayaraghavan R; Anulekha Avinash CK
    Indian J Pathol Microbiol; 2020; 63(4):538-543. PubMed ID: 33154302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
    Inada M; Sato M; Morita S; Kitagawa K; Kawada K; Mitsuma A; Sawaki M; Fujita K; Ando Y
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):729-34. PubMed ID: 20979931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
    Stordal B; Davey R
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
    Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
    Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular docking and molecular dynamics study on the effect of ERCC1 deleterious polymorphisms in ERCC1-XPF heterodimer.
    Priya Doss CG; Nagasundaram N
    Appl Biochem Biotechnol; 2014 Feb; 172(3):1265-81. PubMed ID: 24158589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.